- **Headquarters:** Hangzhou, China
- Dedicated to establishing a globally leading biologics development platform based on viral recombinant technology.
- **Seeking global partners to develop, register and commercialize *DIFF-flu*.**

DIFFERENCE VALUE PROPOSITION

Utilizing viral recombinant technology as the core approach

- Through advancements in viral-attenuation techniques, targeted gene delivery systems, and vector-controllability mechanisms, *DIFF*'s platform—built upon recombinant virus technology—enables broad therapeutic applications across vaccines, oncology treatments, gene therapy approaches, and antiviral drug development.
- DIFF's IP portfolio comprises 80+ patent applications, with 10+ international PCT applications.
- *DIFF*'s product portfolio focuses on **mucosal vaccines** with distinct competitive advantages.
- **First-in-class freeze-dried nasal spray live attenuated influenza vaccine *DIFF-flu*:**
  - Engineered using a proprietary *M2* gene–based attenuation technology to generate a replication-restricted live virus with **minimal virulence and near-zero shedding**, the vaccine is suitable for a **broader population**, including immunocompromised individuals.

M2 GENE-BASED ATTENUATION TECHNOLOGY

- **Global leading *M2* gene-based attenuation technology of replication-restricted live influenza virus.**
  - *M2* gene is one of proteins encoded by M segment of the influenza virus.
  - *DIFF* was the first to discover an attenuation method for replication-restricted influenza virus by specifically manipulating the *M2* gene while preserving *M1* expression, resulting in the attenuation of influenza A virus.
- **Highlight**
  - Significantly attenuated viral pathogenicity
  - Immune responses without sustained pathogenicity in vivo



DISTINCTIVE ADVANTAGES OF DIFF-flu

US Healthcare Market Research Agency's Global Influenza Vaccine Market Growth Projections (2023-2033)



The market grows from 6.7 billion in 2023 to 13.9 billion by 2033.

Limitations of Current Influenza Vaccines:

First-in-Class FreezeDried Nasal Spray Trivalent Live Attenuated Influenza Vaccine: Engineered using a proprietary *M2* gene–based attenuation strategy:

Category	Specifications
Stage	Preclinical. 1st patient enrolling in Q4 2025.
Indications	Influenza
Administration	Nasal Spray
Patent Status	6 patents granted (including 2 authorized in US, Europe and Japan)
Mechanism of Action	• Delivery Method: Attenuated virus via nasal spray, activating nasal mucosal immunity. • Immune Response: - Stimulates IgA antibodies for rapid viral interception. - Activates T-cell immunity. - Induces systemic IgG antibodies. • Triple-Layered Immunity: Mucosal, cellular, humoral.
vs. FluMist (AZ)	• Safety: Superior self-limiting viral shedding → broader population applicability. • Efficacy: Enhanced cross-protection against variants.
vs. Inactivated Vaccines	• Compliance: Higher patient compliance. • Manufacturing: Simpler processes, lower costs, and greater production capacity.

DIFF-flu's Highlights

Superior Safety Profile

- **Minimal viral shedding** observed post-vaccination.
- **Significantly lower virus load** post-vaccination in nasal turbinates and lung tissues.
- No significant toxicity, tissue irritation, or sensitization observed across multiple animal models.
- **Applicable for broader population**, including children, the elderly, and immunocompromised individuals.



Low Tissue Viral Loads in Ferrets Post-immunization



Low Tissue Viral Loads in Immunized Mice

Robust Efficacy

- **Superior cross-protective effect and immunogenicity.** *DIFF-flu* (trivalent vaccine) demonstrated higher levels of protection against heterologous influenza strains with higher levels of IgG antibodies and significantly improved survival rates to 100% compared to a conventional quadrivalent vaccine.



Cross-protective Effect Against Heterologous Influenza Viruses in Mouse Model

- **Effective homologous challenge protection.** *DIFF-flu* effectively protects against matching flu strains with minimal temperature fluctuations and lower virus load in ferrets.
- **Long-lasting immunity:** After vaccination with varying doses of BV, H1N1, and H3N2 attenuated strains, IgG antibody levels in mice remained sustained at peak levels for over 1 year.

Strong Industrial Scalability

- **Production cost reduction:***DIFF-flu* produces 3~5 doses per chicken embryo, compared to other influenza vaccines on the market.
- **Long storage duration** over 1 year as a lyophilized vaccine formulation.
- **Greater convenience, flexibility and accessibility** for individuals and families.

High DTC commercialization potential according to **FDA approved direct-to-consumer (DTC) sales model** for competing products(FluMist). DIFF-flu's high safety and stability support the massive overseas market potential.



FDA NEWS RELEASE

FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration

First Influenza Vaccine That Does Not Need to be Administered by a Health Care Provider

For Immediate Release: September 20, 2024

Spanish

Today, the U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age. It is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a health care provider.